Cannabis Investment Report – Private Company Funding Totals (2016‑2017 YTD)
Summary
The document lists aggregate capital raised by private cannabis‑related firms and a few deal specifics. It contains no references to high‑ranking officials, government agencies, foreign leaders, or al Total capital raised by private cannabis companies grew from $256 M in 2016 to $483 M YTD 2017. Number of deals increased from 65 to 102 in the same period. Largest disclosed private deals in 2017 we
This document is from the House Oversight Committee Releases.
View Source CollectionPersons Referenced (2)
Tags
Related Documents (6)
Ackrell Capital Cannabis Investment Report compares market size to alcohol, coffee, tobacco, and pharmaceuticals
The document is a commercial investment analysis with no mention of political figures, government agencies, or alleged misconduct. It offers no actionable leads for investigations and contains only pu Provides estimated penetration rates and consumer spending for cannabis versus other legal substance Claims U.S. legal cannabis market size aligns with other retail markets. Published by Ackrell Capi
Cannabis Investment Report – Ackrell Capital (Dec 2017) – Product Overview
The passage is a marketing‑style product description of cannabis flower and concentrates. It contains no references to political figures, government agencies, financial misconduct, or foreign influenc Describes cannabis flower characteristics and typical THC/CBD levels. Lists popular strain names and concentrate types. Claims 100% pesticide‑free product and FINRA/SIPC membership.
Ackrell Capital Cannabis OTC Market Valuation Table (2017)
The document is a financial listing of small OTC cannabis companies with market metrics. It contains no references to influential political figures, government agencies, or alleged misconduct, offerin Provides EV multiples and stock price discounts for over 40 cannabis firms. Compiled by Ackrell Capital, a FINRA/SIPC member. Data dated November 30, 2017.
Ackrell Capital report shows modest capital raised by U.S. publicly traded cannabis companies in 2017
The passage provides only aggregate financial data on small, largely unprofitable cannabis firms with no mention of high‑profile individuals, government agencies, or illicit activity. It lacks specifi Only $268 million total equity and debt raised by listed cannabis firms in the 12‑month period endin Most companies had little to no revenue and were not profitable. A single large $317 million finan
Ackrell Capital Cannabis Company Financial Metrics Table
The document is a plain financial summary of cannabis companies listed on the Canadian Securities Exchange with no mention of influential actors, misconduct, or controversial transactions. It offers n Provides market cap, revenue, EBITDA, and valuation multiples for dozens of cannabis firms. Includes percentages of stock price below enterprise value. No names of political figures, government agenc
Ackrell Capital Cannabis Investment Report – Terpene Benefits Overview (Dec 2017)
The passage is a generic industry report describing terpene profiles and alleged medicinal benefits. It contains no references to high‑profile individuals, government agencies, financial transactions, Describes therapeutic claims for various cannabis terpenes (myrcene, pinene, limonene, camphene). Provides a table of purported medical benefits (antianxiety, anti‑inflammatory, etc.). Published by A
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.